Literature DB >> 15932876

Contribution of the carboxyl terminus of the VPAC1 receptor to agonist-induced receptor phosphorylation, internalization, and recycling.

Christelle Langlet1, Ingrid Langer, Pascale Vertongen, Nathalie Gaspard, Jean-Marie Vanderwinden, Patrick Robberecht.   

Abstract

When exposed to vasoactive intestinal peptide (VIP), the human wild type VPAC1 receptor expressed in Chinese hamster ovary (CHO) cells is rapidly phosphorylated, desensitized, and internalized in the endosomal compartment and is not re-expressed at the cell membrane within 2 h after agonist removal. The aims of the present work were first to correlate receptor phosphorylation level to internalization and recycling, measured by flow cytometry and in some cases by confocal microscopy using a monoclonal antibody that did not interfere with ligand binding, and second to identify the phosphorylated Ser/Thr residues. Combining receptor mutations and truncations allowed identification of Ser250 (in the second intracellular loop), Thr429, Ser435, Ser448 or Ser449, and Ser455 (all in the distal part of the C terminus) as candidates for VIP-stimulated phosphorylation. The effects of single mutations were not additive, suggesting alternative phosphorylation sites in mutated receptors. Replacement of all of the Ser/Thr residues in the carboxyl-terminal tail and truncation of the domain containing these residues completely inhibited VIP-stimulated phosphorylation and receptor internalization. There was, however, no direct correlation between receptor phosphorylation and internalization; in some truncated and mutated receptors, a 70% reduction in phosphorylation had little effect on internalization. In contrast to results obtained on the wild type and all of the mutated or truncated receptors that still underwent phosphorylation, internalization of the severely truncated receptor was reversed within 2 h of incubation in the absence of the agonist. Receptor recovery was blocked by monensin, an endosome inhibitor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15932876     DOI: 10.1074/jbc.M500449200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

Authors:  Rebecca J Hermann; Travis Van der Steen; Emilie E Vomhof-Dekrey; Sejaa Al-Badrani; Steve B Wanjara; Jarrett J Failing; Jodie S Haring; Glenn P Dorsam
Journal:  J Immunol Methods       Date:  2011-11-04       Impact factor: 2.303

2.  Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells.

Authors:  Israel Rubinstein; Imre Soos; Hayat Onyuksel
Journal:  Chem Biol Interact       Date:  2007-04-06       Impact factor: 5.192

Review 3.  Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.

Authors:  Kailash N Pandey
Journal:  Can J Physiol Pharmacol       Date:  2011-08-04       Impact factor: 2.273

4.  The Arabidopsis ZED1 pseudokinase is required for ZAR1-mediated immunity induced by the Pseudomonas syringae type III effector HopZ1a.

Authors:  Jennifer D Lewis; Amy Huei-Yi Lee; Jana A Hassan; Janet Wan; Brenden Hurley; Jacquelyn R Jhingree; Pauline W Wang; Timothy Lo; Ji-Young Youn; David S Guttman; Darrell Desveaux
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

Review 5.  The functional genomics of guanylyl cyclase/natriuretic peptide receptor-A: perspectives and paradigms.

Authors:  Kailash N Pandey
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

Review 6.  Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs?

Authors:  James Barwell; Joseph J Gingell; Harriet A Watkins; Julia K Archbold; David R Poyner; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

7.  Pharmacological properties of Chinese hamster ovary cells coexpressing two vasoactive intestinal peptide receptors (hVPAC1 and hVPAC2).

Authors:  Ingrid Langer; Nathalie Gaspard; Patrick Robberecht
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

8.  Caveolae-dependent internalization and homologous desensitization of VIP/PACAP receptor, VPAC₂, in gastrointestinal smooth muscle.

Authors:  Sunila Mahavadi; Sayak Bhattacharya; Jennnifer Kim; Sally Fayed; Othman Al-Shboul; John R Grider; Karnam S Murthy
Journal:  Peptides       Date:  2013-03-15       Impact factor: 3.750

9.  Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation.

Authors:  Kaijun Zhang; Mohan R Aruva; Nylla Shanthly; Christopher A Cardi; Chirag A Patel; Satish Rattan; Gregory Cesarone; Eric Wickstrom; Mathew L Thakur
Journal:  Regul Pept       Date:  2007-07-06

10.  Illuminating the life of GPCRs.

Authors:  Ilka Böhme; Annette G Beck-Sickinger
Journal:  Cell Commun Signal       Date:  2009-07-14       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.